| The blood-brain barrier: Bottleneck in brain drug development | 2005/01/01 | English | 1,664 |
| Medicinal chemical properties of successful central nervous system drugs | 2005/10/01 | English | 968 |
| Biomarkers: Potential uses and limitations | 2004/04/01 | English | 537 |
| Blood-brain barrier active efflux transporters: ATP-binding cassette gene family | 2005/01/01 | English | 528 |
| Toxin-induced models of Parkinson’s disease | 2005/07/01 | English | 482 |
| Rodent models of focal stroke: Size, mechanism, and purpose | 2005/07/01 | English | 468 |
| Cerebrospinal fluid protein biomarkers for Alzheimer’s disease | 2004/04/01 | English | 301 |
| Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery | 2005/10/01 | English | 285 |
| Animal models of head trauma | 2005/07/01 | English | 283 |
| Neuroprotection and acute spinal cord injury: A reappraisal | 2004/01/01 | English | 275 |
| Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults | 2004/01/01 | English | 263 |
| Drug transport to brain with targeted nanoparticles | 2005/01/01 | English | 259 |
| Neuroprotection for ischemic stroke: Two decades of success and failure | 2004/01/01 | English | 257 |
| Cell therapy in Parkinson’s disease | 2004/10/01 | English | 219 |
| Biomarkers and surrogate markers: An FDA perspective | 2004/04/01 | English | 204 |
| Neuronal death/survival signaling pathways in cerebral ischemia | 2004/01/01 | English | 196 |
| Huntington’s disease genetics | 2004/04/01 | English | 196 |
| Neuroimaging in traumatic brain imaging | 2005/04/01 | English | 186 |
| Contemporary assessment and pharmacotherapy of Tourette syndrome | 2006/04/01 | English | 175 |
| Hypoxic preconditioning protects against ischemic brain injury | 2004/01/01 | English | 173 |
| Biomarkers of Alzheimer disease in plasma | 2004/04/01 | English | 166 |
| Hypothermic neuroprotection | 2006/04/01 | English | 160 |
| Neurodegeneration and neuroprotection in Parkinson disease | 2004/01/01 | English | 159 |
| Behavioral tests for preclinical intervention assessment | 2006/10/01 | English | 159 |
| Active efflux across the blood-brain barrier: Role of the solute carrier family | 2005/01/01 | English | 148 |
| The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies | 2005/07/01 | English | 144 |
| Targeting chronic and neuropathic pain: The N-type calcium channel comes of age | 2005/10/01 | English | 142 |
| Innovative approaches for the development of antidepressant drugs: Current and future strategies | 2005/10/01 | English | 139 |
| Immune problems in central nervous system cell therapy | 2004/10/01 | English | 135 |
| Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems | 2005/01/01 | English | 132 |